Novo Nordisk’s troubled Indiana site hit with Form 483 following FDA re-inspection
Despite previous corrective actions, a former Catalent site in Bloomington, Indiana — acquired in late 2024 by Novo Nordisk — continues to be plagued with regulatory problems. Following an April 2026 re-inspection, the FDA cited Novo Nordisk’s fill-finish …